These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 27040924)

  • 1. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
    Wang K; Liu T; Ge N; Liu L; Yuan X; Liu J; Kong F; Wang C; Ren H; Yan K; Hu S; Xu Z; Björkholm M; Fan Y; Zhao S; Liu C; Xu D
    Oncotarget; 2014 Dec; 5(23):12428-39. PubMed ID: 25474136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
    Zhang YH; Xie JJ; Wang JG; Wang Y; Zhan XH; Gao J; He HY
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1216-1222. PubMed ID: 38058037
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
    Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological significance of TERT promoter mutation in papillary urothelial neoplasm of low malignant potential.
    Wang CC; Huang CY; Jhuang YL; Chen CC; Jeng YM
    Histopathology; 2018 Apr; 72(5):795-803. PubMed ID: 29193225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
    Vail E; Zheng X; Zhou M; Yang X; Fallon JT; Epstein JI; Zhong M
    Ann Diagn Pathol; 2015 Oct; 19(5):301-5. PubMed ID: 26239299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
    Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
    Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.
    Wang K; Liu T; Liu C; Meng Y; Yuan X; Liu L; Ge N; Liu J; Wang C; Ren H; Yan K; Hu S; Xu Z; Fan Y; Xu D
    Oncologist; 2015 Mar; 20(3):263-9. PubMed ID: 25657201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT C228T mutation in non-malignant bladder urothelium is associated with intravesical recurrence for patients with non-muscle invasive bladder cancer.
    Hayashi Y; Fujita K; Nojima S; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Morii E; Nonomura N
    Mol Oncol; 2020 Oct; 14(10):2375-2383. PubMed ID: 32533903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.
    Pakmanesh H; Anvari O; Forey N; Weiderpass E; Malekpourafshar R; Iranpour M; Shahesmaeili A; Ahmadi N; Bazrafshan A; Zendehdel K; Kannengiesser C; Ba I; McKay J; Zvereva M; Hosen MI; Sheikh M; Calvez-Kelm FL
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins.
    Zheng X; Zhuge J; Bezerra SM; Faraj SF; Munari E; Fallon JT; Yang XJ; Argani P; Netto GJ; Zhong M
    J Hematol Oncol; 2014 Jul; 7():47. PubMed ID: 25042800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
    Günes C; Wezel F; Southgate J; Bolenz C
    Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
    Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
    Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation.
    Zhong M; Tian W; Zhuge J; Zheng X; Huang T; Cai D; Zhang D; Yang XJ; Argani P; Fallon JT; Epstein JI
    Am J Surg Pathol; 2015 Jan; 39(1):127-31. PubMed ID: 25118812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer.
    Roggisch J; Ecke T; Koch S
    Urol Oncol; 2020 Mar; 38(3):77.e17-77.e25. PubMed ID: 31521529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma.
    Hayashi Y; Fujita K; Matsuzaki K; Matsushita M; Kawamura N; Koh Y; Nakano K; Wang C; Ishizuya Y; Yamamoto Y; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Uemura M; Imamura R; Takao T; Takada S; Netto GJ; Nonomura N
    Cancer Sci; 2019 May; 110(5):1771-1779. PubMed ID: 30887605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer.
    Avogbe PH; Manel A; Vian E; Durand G; Forey N; Voegele C; Zvereva M; Hosen MI; Meziani S; De Tilly B; Polo G; Lole O; Francois P; Delhomme TM; Carreira C; Monteiro-Reis S; Henrique R; Abedi-Ardekani B; Byrnes G; Foll M; Weiderpass E; McKay J; Jeronimo C; Scelo G; Le Calvez-Kelm F
    EBioMedicine; 2019 Jun; 44():431-438. PubMed ID: 31122840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates.
    Taylor AS; McKenney JK; Osunkoya AO; Chan MP; Al-Ahmadie HA; Spratt DE; Fullen DR; Chinnaiyan AM; Brown NA; Mehra R
    Mod Pathol; 2020 Jun; 33(6):1165-1171. PubMed ID: 31932679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.